Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 13/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 13/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL29816932 | 0.86 | NOS1 (0.33) | HRH4HRH3 | |
| SCHEMBL3633179 | 0.86 | CYP2D6 (0.34) | CYP2D6SLC6A2SLC6A4SLC6A3 | |
| Trifluoroacetic Acid SCHEMBL18150960 | 0.79 | — | — | |
| Trifluoroacetic Acid SCHEMBL3335470 | 0.76 | OPRM1 (0.33) | HRH4HRH3 | |
| Trifluoroacetic Acid SCHEMBL3334450 | 0.75 | HRH4 (0.31) | HRH4HRH3 | |
| SCHEMBL18576314 | 0.74 | — | — | |
| Trifluoroacetic Acid SCHEMBL31026676 | 0.74 | PKM (0.30) | — | |
| Trifluoroacetic Acid SCHEMBL2079996 | 0.74 | HRH4 (0.33) | HRH4HRH3 | |
| Trifluoroacetic Acid SCHEMBL22495565 | 0.73 | CPB2 (0.32) | HRH4HRH3 | |
| Trifluoroacetic Acid SCHEMBL321952 | 0.72 | NOS1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137305-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137305-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | AURKC, AURKA, AURKB | CYP2D6 2839/4885SLC6A2 4258/4885SLC6A4 4210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.